TX-MAVENIR
16.4.2024 13:01:29 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that the Mavenir Digital Enablement (MDE) is now available on Amazon Web Services (AWS) Marketplace.
Mavenir’s Digital Enablement (MDE) Business Support System (BSS) stack with composable architecture allows Communication Service Providers (CSPs) to implement innovative strategies and new selling models quickly, cost-effectively and with minimal risk, with the ability to test models iteratively and speed time-to-market without increasing capital and resource costs. MDE’s comprehensive set of modules already run on AWS – for reduced application-to-infrastructure test times – and span customer management, product catalog, order management, CRM, billing, converged charging, API monetization and network slice charging. With low-code/no-code visual builders and templated solutions-in-a-box, MDE is now available as a one-stop destination and digital marketplace for CSPs looking to implement new or complex models simply and agilely.
MDE offers a low-risk route to introducing profitable new business models such as split or sponsored billing, new package product offerings incorporating third-party solutions, automation for inter-partner manual tasks such as catalog mapping, and notifications mapping for service delivery to improve operational efficiency and the customer experience.
Mavenir’s Digital BSS has achieved platinum certification from TM Forum, with open APIs ensuring seamless integration with existing or new third-party systems and eliminating the need for resource-intensive system integration effort.
Sandeep Singh, Senior Vice President and General Manager for Mavenir’s Digital Business Enablement commented: “Mavenir’s Digital BSS is a transformative solution for service providers looking to stay ahead of the competition and launch innovative offerings in a fast time-to-market. Our arrival on AWS Marketplace is a strategic acceleration of our mission to drive sustainable global network automation and monetization, empowering the world’s operators to roll out advanced digital experiences at scale.”
He added: “By facilitating end-to-end digitization of customer interactions and streamlining collaboration with third-party partners – all within a stable and agile architecture – MDE Digital BSS provides service providers with a complete innovation framework to create seamless, personalized network service experiences for customers, and realize the gains with flexible monetization capabilities.”
John Abraham, Principal Analyst, Appledore Research noted: “One of the main innovation barriers for CSPs is the inflexibility of incumbent legacy BSS ecosystems, which require substantial investment in time, cost, and operational resources to enable new revenue models and service capabilities. Simplifying the path to the timely introduction of new business models and innovative best practices, as Mavenir is enabling with its MDE solution, provides CSPs with a distinct advantage in time to market and TCO.”
The MDE platform not only enables greenfield service providers to bring new services to market rapidly but also empowers brownfield service providers to modernize their legacy stack, accelerate digital transformation, and provides a viable path to migrate to 5G while co-existing with existing technologies (2G/3G/4G). MDE brings marketplace capabilities to service providers to cross sell 3rd Party Partner-led product and services integrated with CSPs and Mobile Virtual Network Operators (MVNOs) worldwide. The platform uses advanced AI-ML engines to derive intelligence from customer and network data, which is then used to recommend new products based on historical behavior, and also delivers categorization capabilities that enable service providers to fully capitalize on their rich datasets – bringing new revenues and boosting customer stickiness.
Notes to editors:
- More information about Mavenir’s Digital BSS:
https://www.mavenir.com/portfolio/mavapps/mavenir-digital-enablement-bss/
- Mavenir’s listing on AWS Marketplace:
https://aws.amazon.com/marketplace/pp/prodview-ylbqlsfj3bmay
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416395684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom